Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies

Rohit Singh, Jessica Williams, Robert Vince

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Substantial progress has been described in the study of puromycin and its analogs for antibiotic properties. However, the peptidase inhibitory activity of related analogs has not been explored as extensively. Specifically, inhibiting aminopeptidases for achieving antitumor effect has been sparsely investigated. Herein, we address this challenge by reporting the synthesis of a series of analogs based on the structural template of puromycin. We also present exhaustive biochemical and in vitro analyses in support of our thesis. Analyzing the structure–activity relationship revealed a steric requirement for maximum potency. Effective inhibitors of Puromycin–Sensitive Aminopeptidase (PSA) are disclosed here. These potential therapeutic agents display superior in vitro antitumor potency against two leukemic cell lines, as compared to known inhibitors of aminopeptidases.

Original languageEnglish (US)
Pages (from-to)325-336
Number of pages12
JournalEuropean Journal of Medicinal Chemistry
Volume139
DOIs
StatePublished - Jan 1 2017

Fingerprint

Puromycin
Aminopeptidases
Hematologic Neoplasms
Peptide Hydrolases
Cells
Anti-Bacterial Agents
Cell Line
In Vitro Techniques
Therapeutics

Keywords

  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Amino acid deprivation response (AADR)
  • Aminopeptidase N (APN)
  • Aminopeptidases
  • Puromycin–sensitive aminopeptidase (PSA)

Cite this

Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies. / Singh, Rohit; Williams, Jessica; Vince, Robert.

In: European Journal of Medicinal Chemistry, Vol. 139, 01.01.2017, p. 325-336.

Research output: Contribution to journalArticle

@article{900e8a7ebe814a04b865a369399b11ae,
title = "Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies",
abstract = "Substantial progress has been described in the study of puromycin and its analogs for antibiotic properties. However, the peptidase inhibitory activity of related analogs has not been explored as extensively. Specifically, inhibiting aminopeptidases for achieving antitumor effect has been sparsely investigated. Herein, we address this challenge by reporting the synthesis of a series of analogs based on the structural template of puromycin. We also present exhaustive biochemical and in vitro analyses in support of our thesis. Analyzing the structure–activity relationship revealed a steric requirement for maximum potency. Effective inhibitors of Puromycin–Sensitive Aminopeptidase (PSA) are disclosed here. These potential therapeutic agents display superior in vitro antitumor potency against two leukemic cell lines, as compared to known inhibitors of aminopeptidases.",
keywords = "Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Amino acid deprivation response (AADR), Aminopeptidase N (APN), Aminopeptidases, Puromycin–sensitive aminopeptidase (PSA)",
author = "Rohit Singh and Jessica Williams and Robert Vince",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.ejmech.2017.07.048",
language = "English (US)",
volume = "139",
pages = "325--336",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies

AU - Singh, Rohit

AU - Williams, Jessica

AU - Vince, Robert

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Substantial progress has been described in the study of puromycin and its analogs for antibiotic properties. However, the peptidase inhibitory activity of related analogs has not been explored as extensively. Specifically, inhibiting aminopeptidases for achieving antitumor effect has been sparsely investigated. Herein, we address this challenge by reporting the synthesis of a series of analogs based on the structural template of puromycin. We also present exhaustive biochemical and in vitro analyses in support of our thesis. Analyzing the structure–activity relationship revealed a steric requirement for maximum potency. Effective inhibitors of Puromycin–Sensitive Aminopeptidase (PSA) are disclosed here. These potential therapeutic agents display superior in vitro antitumor potency against two leukemic cell lines, as compared to known inhibitors of aminopeptidases.

AB - Substantial progress has been described in the study of puromycin and its analogs for antibiotic properties. However, the peptidase inhibitory activity of related analogs has not been explored as extensively. Specifically, inhibiting aminopeptidases for achieving antitumor effect has been sparsely investigated. Herein, we address this challenge by reporting the synthesis of a series of analogs based on the structural template of puromycin. We also present exhaustive biochemical and in vitro analyses in support of our thesis. Analyzing the structure–activity relationship revealed a steric requirement for maximum potency. Effective inhibitors of Puromycin–Sensitive Aminopeptidase (PSA) are disclosed here. These potential therapeutic agents display superior in vitro antitumor potency against two leukemic cell lines, as compared to known inhibitors of aminopeptidases.

KW - Acute lymphoblastic leukemia (ALL)

KW - Acute myeloid leukemia (AML)

KW - Amino acid deprivation response (AADR)

KW - Aminopeptidase N (APN)

KW - Aminopeptidases

KW - Puromycin–sensitive aminopeptidase (PSA)

UR - http://www.scopus.com/inward/record.url?scp=85026921451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026921451&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2017.07.048

DO - 10.1016/j.ejmech.2017.07.048

M3 - Article

VL - 139

SP - 325

EP - 336

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -